Intensity of antianginal therapy in patients referred for coronary angiography: a comparison of fee-for-service and health maintenance organization therapeutic strategies
- PMID: 10761803
- PMCID: PMC6655017
- DOI: 10.1002/clc.4960230307
Intensity of antianginal therapy in patients referred for coronary angiography: a comparison of fee-for-service and health maintenance organization therapeutic strategies
Abstract
Background: No formal criteria have been developed to guide medical therapy for angina prior to revascularization, and no comparisons have been made between health maintenance organization (HMO) and fee-for-service (FFS) hospitals with respect to angina treatment.
Hypothesis: Using a literature-based measure of medical intensity, we tested the hypothesis that there is no difference in anginal medical therapeutic intensity between HMO and FFS systems.
Methods: For each antianginal drug, we developed a model from which an intensity score between 0 and 100 could be calculated. Average and maximal daily doses of drug were fit to a sigmoid curve such that they represented scores of 50 and 99, respectively. Overall intensity scores were obtained by weighted and unweighted averaging of three scores from nitrates, calcium-channel blockers, and beta blockers. This model was applied to 199 patients undergoing angiography at an FFS and an HMO hospital.
Results: HMO patients were taking more classes of antianginal drug (1.9 vs. 1.0, p < 0.001). Overall unweighted (17.7 vs. 11.7, p = 0.02) and weighted (27.3 vs. 16.9, p = 0.003) intensity scores for both HMO and FFS patients were low. HMO intensity scores for the use of beta blockers were greater than FFS scores (19.2 vs. 9.6, p = 0.002). The intensity scores for the use of nitrates and calcium blockers were similar.
Conclusions: Models for the measurement of anginal medical therapy intensity can provide important information regarding medical therapy prior to revascularization. The overall intensity of medical therapy was low in both health care systems. These findings have important implications for patient management, guideline development, and national healthcare policy.
References
-
- Thadani U, Chohan A: Chronic stable angina pectoris, strategies for effective drug therapy. Postgrad Med 1995; 98: 175–176 - PubMed
-
- Carbajal EV, Deedwania PC: Contemporary approaches in medical management of patients with stable coronary artery disease. Med Clin North Am 1995; 79: 1063–1084 - PubMed
-
- Mark DB, Nelson CL, Califf RM, Harrell FE, Lee KL, Jones RH, Fortin DF, Stack RS, Glower DD, Smith LR, DeLong ER, Smith PK, Reves JG, Jollis JG, Tcheng JE, Muhlbaier LH, Lowe JE, Phillips HR, Pryor DB: Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994; 89: 2015–2025 - PubMed
-
- Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB, McCallister BD, Smith SC, Ullyot DJ: Guidelines for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1993; 22: 2033–2054 - PubMed
-
- Anonymous : Guidelines and indications for coronary artery bypass graft surgery. J Am Coll Cardiol 1991; 17: 543–589 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical